» Articles » PMID: 27573791

Reliability of Trained Dogs to Alert to Hypoglycemia in Patients With Type 1 Diabetes

Overview
Specialty Endocrinology
Date 2016 Aug 31
PMID 27573791
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We examined the reliability of trained dogs to alert to hypoglycemia in individuals with type 1 diabetes.

Methods: Patients with type 1 diabetes who currently used diabetes alert dogs participated in this exploratory study. Subjects reported satisfaction, perceived dog glucose sensing ability and reasons for obtaining a trained dog. Reliability of dog alerts was assessed using capillary blood glucose (CBG) and blinded continuous glucose monitoring (CGM) as comparators in 8 subjects (age 4-48). Hypoglycemia was defined as CBG or CGM <70 mg/dL.

Results: Dog users were very satisfied (8.9/10 on a Likert-type scale) and largely confident (7.9/10) in their dog's ability to detect hypoglycemia. Detection of hypoglycemia was the primary reason for obtaining a trained dog. During hypoglycemia, spontaneous dog alerts occurred at a rate 3.2 (2.0-5.2, 95% CI) times higher than during euglycemia (70-179 mg/dL). Dogs provided timely alerts in 36% (sensitivity) of all hypoglycemia events (n = 45). Due to inappropriate alerts, the PPV of a dog alert for hypoglycemia was 12%. When there was concurrence of a hypoglycemic event between the dog alert and CGM (n = 30), CGM would have alerted prior to the dog in 73% of events (median 22-minute difference).

Conclusions: This is the first study evaluating reliability of trained dogs to alert to hypoglycemia under real-life conditions. Trained dogs often alert a human companion to otherwise unknown hypoglycemia; however due to high false-positive rate, a dog alert alone is unlikely to be helpful in differentiating hypo-/hyper-/euglycemia. CGM often detects hypoglycemia before a trained dog by a clinically significant margin.

Citing Articles

Use of trained scent dogs for detection of COVID-19 and evidence of cost-saving.

Mutesa L, Misbah G, Remera E, Ebbers H, Schalke E, Tuyisenge P Front Med (Lausanne). 2022; 9:1006315.

PMID: 36530913 PMC: 9751420. DOI: 10.3389/fmed.2022.1006315.


Web-Based Skin Cancer Assessment and Classification Using Machine Learning and Mobile Computerized Adaptive Testing in a Rasch Model: Development Study.

Yang T, Chien T, Lai F JMIR Med Inform. 2022; 10(3):e33006.

PMID: 35262505 PMC: 9282670. DOI: 10.2196/33006.


The Potential Use of Volatile Biomarkers for Malaria Diagnosis.

Chai H, Chua K Diagnostics (Basel). 2021; 11(12).

PMID: 34943481 PMC: 8700171. DOI: 10.3390/diagnostics11122244.


Canine Olfaction: Physiology, Behavior, and Possibilities for Practical Applications.

Kokocinska-Kusiak A, Woszczylo M, Zybala M, Maciocha J, Barlowska K, Dzieciol M Animals (Basel). 2021; 11(8).

PMID: 34438920 PMC: 8388720. DOI: 10.3390/ani11082463.


Canine olfactory detection and its relevance to medical detection.

Jendrny P, Twele F, Meller S, Osterhaus A, Schalke E, Volk H BMC Infect Dis. 2021; 21(1):838.

PMID: 34412582 PMC: 8375464. DOI: 10.1186/s12879-021-06523-8.


References
1.
Rooney N, Morant S, Guest C . Investigation into the value of trained glycaemia alert dogs to clients with type I diabetes. PLoS One. 2013; 8(8):e69921. PMC: 3737201. DOI: 10.1371/journal.pone.0069921. View

2.
Maranda L, Gupta O . Association between Responsible Pet Ownership and Glycemic Control in Youths with Type 1 Diabetes. PLoS One. 2016; 11(4):e0152332. PMC: 4841520. DOI: 10.1371/journal.pone.0152332. View

3.
Cryer P . Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev. 1999; 15(1):42-6. DOI: 10.1002/(sici)1520-7560(199901/02)15:1<42::aid-dmrr1>3.0.co;2-b. View

4.
Beck R, Calhoun P, Kollman C . Use of continuous glucose monitoring as an outcome measure in clinical trials. Diabetes Technol Ther. 2012; 14(10):877-82. PMC: 3459006. DOI: 10.1089/dia.2012.0079. View

5.
Ahn C, Hu F, Schucany W . Sample Size Calculation for Clustered Binary Data with Sign Tests Using Different Weighting Schemes. Stat Biopharm Res. 2011; 3(1):65-72. PMC: 3040008. DOI: 10.1198/sbr.2010.10021. View